Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atezolizumab/bevacizumab may offer benefit to patients with RCC

Publish date:: November 25, 2019

Key clinical point: Atezolizumab plus bevacizumab may be useful in patients with advanced renal cell carcinoma who are PD-L1–positive.

Major finding: The overall response rate among such patients was 60% compared with 19% in PD-L1–negative patients.

Study details: The open-label study comprised 60 patients.

Disclosures: Bristol-Myers Squibb sponsored the study. Dr. McGregor reporter consultancy roles for Bayer AG, Seattle Genetics, Astellas Pharma, Exelixis, AstraZeneca, Genentech, Roche, Nextar, Janssen Oncology, Pfizer, EMD Serono Research.

Citation:

McGregor BA et al. J Clin Oncol. 2019 Nov 13. doi: 10.1200/JCO.19.01882.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,